Nevertheless, our results not only support the use of ITGB2 and the newly identified SCLC-ITGB2-sig as diagnostic markers for SCLC, but also as targets to develop therapeutic strategies against this extremely aggressive type of LC. This evidence concerns the gene ITGB2 and small cell lung carcinoma.